Simon Saxby Joins Board at Selcia
News Jun 28, 2010
Simon Saxby is currently Vice-President Biologics of RecipharmCobra Biologics, a Swedish contract development and manufacturing company and has worldwide responsibility for the manufacturing of biologics. Simon has over 25 years experience in the biotechnology industry, including several CEO positions, most recently at Cobra Biomanufacturing plc and Alpha Biologics. He brings a blend of technical, business, sales and marketing skills and senior management, fund-raising and M&A experience.
Commenting on the appointment, Managing Director of Selcia, Dr Hans Fliri said: “I am delighted to welcome Simon to the management team. Simon brings with him his considerable international experience, technical knowledge and commercial expertise. We look forward to Simon helping us accelerate our UK and international market development plans”.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018